- Home
- QIPT vs CGEN Comparison
QIPT vs CGEN Comparison
Compare QIPT & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QIPT
- CGEN
- Stock Information
- Founded
- QIPT 1993
- CGEN 1993
- Country
- QIPT United States
- CGEN Israel
- Employees
- QIPT N/A
- CGEN N/A
- Industry
- QIPT
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QIPT
- CGEN Health Care
- Exchange
- QIPT Nasdaq
- CGEN Nasdaq
- Market Cap
- QIPT 104.7M
- CGEN 125.3M
- IPO Year
- QIPT N/A
- CGEN 2000
- Fundamental
- Price
- QIPT $2.41
- CGEN $1.57
- Analyst Decision
- QIPT Buy
- CGEN
- Analyst Count
- QIPT 2
- CGEN 0
- Target Price
- QIPT $3.15
- CGEN N/A
- AVG Volume (30 Days)
- QIPT 278.0K
- CGEN 286.4K
- Earning Date
- QIPT 12-15-2025
- CGEN 11-10-2025
- Dividend Yield
- QIPT N/A
- CGEN N/A
- EPS Growth
- QIPT N/A
- CGEN N/A
- EPS
- QIPT N/A
- CGEN N/A
- Revenue
- QIPT $238,378,000.00
- CGEN $6,903,000.00
- Revenue This Year
- QIPT N/A
- CGEN N/A
- Revenue Next Year
- QIPT $28.69
- CGEN $208.08
- P/E Ratio
- QIPT N/A
- CGEN N/A
- Revenue Growth
- QIPT N/A
- CGEN N/A
- 52 Week Low
- QIPT $1.35
- CGEN $1.13
- 52 Week High
- QIPT $3.27
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- QIPT 52.68
- CGEN 45.22
- Support Level
- QIPT $2.15
- CGEN $1.51
- Resistance Level
- QIPT $2.39
- CGEN $1.66
- Average True Range (ATR)
- QIPT 0.11
- CGEN 0.10
- MACD
- QIPT 0.01
- CGEN -0.01
- Stochastic Oscillator
- QIPT 76.12
- CGEN 25.00
About QIPT Quipt Home Medical Corp.
Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients. The Company operates in one business segment, which is the sale and rental of medical equipment and related devices. The company's services consist of Daily and Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea and PAP Treatment.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.